

GALAXY RESOURCES LTD (GXY)

Almost there

GXY has announced that it has almost commissioned the Mt Cattlin lithium facility. Over the next two weeks the aim is for 24-hour continuous production. Product specifications still need to be confirmed, and hence it is too early, in our view, to declare commercial production, but we are getting very close.

CY17 could be an upgrade, but for now happy to go back and wait.

The Company guidance is to reach 1.6Mtpa throughput for 160kt pa of spodumene at 50% recoveries. Phase 2 is the plan to install flotation to increase yields to >80% (256ktpa). The expectation is that recoveries can be optimised to ~70% without a float (>224kt pa), but we have gone back to be more conservative and assume ~50% recoveries for most of CY17. In late CY17 we assume an additional \$20m of capex (flotation circuit) is invested, which then gradually builds recoveries to 85% by 2H18. If the circuit, pre-flotation, does recovery lithium as envisaged (rather than only 50%), we estimate CY17 production forecasts should be increased. However, given the delays in commissioning from hardrock lithium projects, we are happy to stay on the conservative end (and slightly below lower end guidance). We assume CY17 production of 134kt. Our selling price assumptions are unchanged, and we expect higher spodumene prices CY17 (US\$750/t).

Refinance required

The Company recently announced a \$16m increase to the working capital facility (brings it to \$47m, and hence Mt Cattlin is now fully funded). There is A\$16m due 31 March 2017 and A\$31m is due 24 February 2017, neither of which will be payable without a refinance. The Company says that it is "now well advanced in negotiations with an international bank to provide a revolving facility for an amount of up to US\$30 million, which will be applied to refinancing its existing facilities". Given the cash flows the project should deliver, we believe refinance should be easily achievable.

Maintain Buy

Our last report was before the completion of the merger, and we had a Buy recommendation on the Mergeco. We are now in the final teething stages of the Mt Cattlin restart, and soon (sometime in CY17) GXY should be producing strong free cash flow. There are still risks to production, in our view, but equally we believe there are still upside risks to spodumene prices over coming years. Hence, we retain our Buy for GXY. Assuming no value for Sal De Vida or James Bay, our valuation would be 25cps. Our base case (assuming value for all three assets) is 58cps.

Fig. 1: Hartleys Mt Cattlin Assumptions

Mt Cattlin Production Summary	Unit	Dec 16	Dec 17	Dec 18	Dec 19	Dec 20	Dec 21
Processed Mill Throughput	Mt	0.03	1.36	1.55	1.55	1.55	1.55
Mined grade Li	%		1.2%	1.2%	1.2%	1.2%	1.2%
Produced Spodumene - Technical	kt	0.0	0.0	0.0	0.0	0.0	0.0
Produced Spodumene - Battery	kt	2	134	223	253	253	253
Produced Tantalite	klb pa	4	231	314	314	314	314
Produced Spodumene - Battery Eq	kt	3	147	239	269	275	275
LCE equiv	Kt	0	20	32	36	37	37

Source: Hartleys Research

Share Price	\$0.350
Valuation	\$0.58
Price Target (12 month)	\$0.52

Brief Business Description:

Commissioning the Mt Cattlin spodumene mine. Developing the large lithium brine operation Sal de Vida.

Hartleys Brief Investment Conclusion

One of the few Companies that is in production of lithium ore and has offtake agreements for product. Growth potential from James Bay project and Sal De Vida.

Chairman & MD

Martin Rowley (Exec. Chairman)

Anthony Tse (MD)

Major Shareholders

Company Address

Suite 8/18 Kearns Cr
Ardross, WA, 6153


Issued Capital 1832.5m
- fully diluted 1881.5m

Market Cap A\$641.4m
- fully diluted A\$658.5m

Cash (31 Dec 16e) A\$2.0m

Debt (31 Dec 16e) A\$47.0m

	Prelim. (A\$m)	CY17e	CY18e	CY19e
Prod (Li Spod. eq)	147.2	239.3	269.0	269.0
Op Cash Flw	103.7	145.3	163.8	163.8
Norm NPAT	56.0	139.0	150.8	150.8



Trent Barnett

Head of Research

Ph: +61 8 9268 3052

E: trent_barnett@hartleys.com.au

Fig. 2: Key Assumptions and Risks for valuation

Assumption	Risk of not realising assumption	Downside risk to valuation if assumption is incorrect	Comment
~15 year mine life	Low	Meaningful	This appears reasonable based on current resources
Ramp-up to 1.6mtpa in CY16	Upside/downside	Meaningful	This seems reasonable given infrastructure in place, and potentially ramp-up could be faster than our assumptions
Recoveries take time to reach 70%, and capital is required to achieve 85%	Upside/downside	Meaningful	Hopefully our recovery estimates are too low, and the plant can be optimised quickly to achieve 70%
Spodumene prices in line with our estimates	Upside/downside	Meaningful	We assume prices are yet to peak
Sal De Vida is developed	High	High	Sal De Vida appears highly economic, but will take time for first cash flows
No new financing	Low	Meaningful	We assume the project is fully funded.
Exploration value	Moderate	Meaningful	We assume modest exploration value.
<hr/>			
<i>Conclusion</i>	<i>Selling prices of spodumene and lithium carbonate and the development of Sal de Vida are significant risks to valuation.</i>		

Source: Hartleys

PRICE TARGET

We have reduced our price target to \$0.52 (from 69cps previously).


Price Target Methodology	Weighting	Spot	12 mth out
NPV base case	65%	\$0.58	\$0.64
NPV base case Mt Cattlin only	15%	\$0.25	\$0.27
NPV at spot commodity and fx prices	10%	\$0.63	\$0.70
Net cash	10%	\$0.00	\$0.00
Risk weighted composite		\$0.48	
12 Months Price Target		\$0.52	
<hr/>			
Shareprice - Last - GXY		\$0.350	
12 mth total return (% to 12mth target + dividend)		50%	

Source: Hartleys Estimate

RISKS


The largest risk for GXY are the selling prices of spodumene and lithium carbonate. Other risks are similar to most producers: mine planning, mill performance, force-majeure, counter party risks, mine life extensions, expansions.

Fig. 3: *Using Hartleys base case commodity forecasts*



Source: Hartleys Estimates, IRESS

Fig. 4: *Using spot commodity prices*



Source: Hartleys Estimates

HARTLEYS CORPORATE DIRECTORY

Research

Trent Barnett	Head of Research	+61 8 9268 3052
Mike Millikan	Resources Analyst	+61 8 9268 2805
John Macdonald	Resources Analyst	+61 8 9268 3020
Michael Scantlebury	Junior Analyst	+61 8 9268 3045
Janine Bell	Research Assistant	+61 8 9268 2831

Corporate Finance

Dale Bryan	Director & Head of Corp Fin.	+61 8 9268 2829
Richard Simpson	Director	+61 8 9268 2824
Paul Fryer	Director	+61 8 9268 2819
Ben Wale	Associate Director	+61 8 9268 3055
Ben Crossing	Associate Director	+61 8 9268 3047
Stephen Kite	Associate Director	+61 8 9268 3050
Scott Weir	Associate Director	+61 8 9268 2821
Rhys Simpson	Manager	+61 8 9268 2851

Registered Office

Level 6, 141 St Georges Tce Postal Address:

PerthWA 6000	GPO Box 2777
Australia	Perth WA 6001
PH:+61 8 9268 2888	FX: +61 8 9268 2800
www.hartleys.com.au	info@hartleys.com.au

Note: personal email addresses of company employees are structured in the following manner:firstname_lastname@hartleys.com.au

Hartleys Recommendation Categories

Buy	Share price appreciation anticipated.
Accumulate	Share price appreciation anticipated but the risk/reward is not as attractive as a "Buy". Alternatively, for the share price to rise it may be contingent on the outcome of an uncertain or distant event. Analyst will often indicate a price level at which it may become a "Buy".
Neutral	Take no action. Upside & downside risk/reward is evenly balanced.
Reduce / Take profits	It is anticipated to be unlikely that there will be gains over the investment time horizon but there is a possibility of some price weakness over that period.
Sell	Significant price depreciation anticipated.
No Rating	No recommendation.
Speculative Buy	Share price could be volatile. While it is anticipated that, on a risk/reward basis, an investment is attractive, there is at least one identifiable risk that has a meaningful possibility of occurring, which, if it did occur, could lead to significant share price reduction. Consequently, the investment is considered high risk.

Disclaimer/Disclosure

The author of this publication, Hartleys Limited ABN 33 104 195 057 ("Hartleys"), its Directors and their Associates from time to time may hold shares in the security/securities mentioned in this Research document and therefore may benefit from any increase in the price of those securities. Hartleys and its Advisers may earn brokerage, fees, commissions, other benefits or advantages as a result of a transaction arising from any advice mentioned in publications to clients.

Any financial product advice contained in this document is unsolicited general information only. Do not act on this advice without first consulting your investment adviser to determine whether the advice is appropriate for your investment objectives, financial situation and particular needs. Hartleys believes that any information or advice (including any financial product advice) contained in this document is accurate when issued. Hartleys however, does not warrant its accuracy or reliability. Hartleys, its officers, agents and employees exclude all liability whatsoever, in negligence or otherwise, for any loss or damage relating to this document to the full extent permitted by law.

Institutional Sales

Carrick Ryan	+61 8 9268 2864
Justin Stewart	+61 8 9268 3062
Simon van den Berg	+61 8 9268 2867
Chris Chong	+61 8 9268 2817
Digby Gilmour	+61 8 9268 2814
Cooper Rogers	+61 8 9268 3053

Wealth Management

Nicola Bond	+61 8 9268 2840
Bradley Booth	+61 8 9268 2873
Adrian Brant	+61 8 9268 3065
Nathan Bray	+61 8 9268 2874
Sven Burrell	+61 8 9268 2847
Simon Casey	+61 8 9268 2875
Tony Chien	+61 8 9268 2850
Tim Cottee	+61 8 9268 3064
David Cross	+61 8 9268 2860
Nicholas Draper	+61 8 9268 2883
John Featherby	+61 8 9268 2811
Ben Fleay	+61 8 9268 2844
James Gatti	+61 8 9268 3025
John Goodlad	+61 8 9268 2890
Andrew Gribble	+61 8 9268 2842
David Hainsworth	+61 8 9268 3040
Neil Inglis	+61 8 9268 2894
Murray Jacob	+61 8 9268 2892
Gavin Lehmann	+61 8 9268 2895
Shane Lehmann	+61 8 9268 2897
Steven Loxley	+61 8 9268 2857
Andrew Macnaughtan	+61 8 9268 2898
Scott Metcalf	+61 8 9268 2807
David Michael	+61 8 9268 2835
Jamie Moullin	+61 8 9268 2856
Chris Munro	+61 8 9268 2858
Michael Munro	+61 8 9268 2820
Ian Parker	+61 8 9268 2810
Charlie Ransom	+61 8 9268 2868
Mark Sandford	+61 8 9268 3066
David Smyth	+61 8 9268 2839
Greg Soudure	+61 8 9268 2834
Sonya Soudure	+61 8 9268 2865
Dirk Vanderstruyf	+61 8 9268 2855
Samuel Williams	+61 8 9268 3041
Jayne Walsh	+61 8 9268 2828